CLAIM CARDS
Claim Cards
Atomic claims extracted from accepted Researka artifacts, with source support, contradiction state, and provenance links when available.
Filtered to publication b18dacf3-a86e-4d0d-b54f-ea476005c515
exploratory
In advanced atherosclerotic Apoe-/- mouse models, does ABT-263 senolytic treatment support a narrow warning that senescent-cell clearance can reduce smooth-muscle-associated plaque features while simultaneously increasing endothelial-to-mesenchymal transition and mortality risk, and should this signal be framed as a therapeutic-window concern rather than as evidence that senolytics are broadly harmful or broadly beneficial?
Contradiction: none
Sources: 4
exploratoryThis submission uses the retained Researka v4 senolytic evidence run from 2026-05-17. The load-bearing receipts are three A-core numeric facts from the same 2024 JCI Insight source on advanced atherosclerotic Apoe-/- mice treated with ABT-263. Additional source-bundle entries provide contextual senolytic receipts from the same run so reviewers can see the broader topic boundary, but they are not used to broaden the main claim.
Contradiction: none
Sources: 4
exploratoryThe central evidence is source-concentrated and preclinical. That is acceptable only for a frontier warning memo because the signal is counter-consensus and internally coherent: the same model/source reports plaque-cell reduction, EndoMT increase, and mortality risk. Contextual bundle papers cover adjacent senolytic biology, but the thesis should remain limited to advanced plaque biology and ABT-263 rather than general anti-aging use.
Contradiction: none
Sources: 4
exploratoryfact_id=12624: increased EC contributions to lesions via EC-to-mesenchymal transition (EndoMT) by 60% in advanced atherosclerotic Apoe-/- mice fed western diet; intervention: ABT-263 at 100 mg/kg or 50 mg/kg; source DOI: 10.1172/jci.insight.173863
Contradiction: none
Sources: 4
exploratoryTaken together, these receipts support a narrow interpretation: ABT-263 may clear or reduce plaque-associated smooth muscle cells while worsening features linked to plaque instability and survival. The important claim is not that senolytics fail globally; it is that late-stage vascular plaque context may invert the expected benefit-risk story.
Contradiction: none
Sources: 4
exploratoryUseful falsification work includes independent replication in advanced plaque models, dose-response separation of smooth-muscle-cell loss from EndoMT induction, comparison with non-ABT-263 senolytics, and human vascular safety evidence. A broader review should also test whether earlier-stage plaque, lower-dose exposure, or intermittent treatment changes the direction of the risk signal.
Contradiction: none
Sources: 4
exploratoryThe current evidence supports submitting a cautious Researka alpha memo: senolytic ABT-263 may backfire in advanced plaques by coupling plaque-cell reduction with EndoMT and mortality risk. The conclusion should be published only as a bounded frontier signal with explicit single-source and preclinical caveats, not as settled evidence against senolytic therapy.
Contradiction: none
Sources: 4